5 names are moving together; 60% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | +2.6% | Group member |
| PRAX | Praxis Precision Medicines, Inc | Healthcare | +4.2% | Group member |
| ALMS | Alumis Inc. | Healthcare | -2.8% | Group member |
| ABVX | Abivax SA | Healthcare | -0.9% | Group member |
| CELC | Celcuity Inc. | Healthcare | +6.8% | Most structurally connected |
Cohort
5 namesParticipation
60% this sessionObserved history
1 daily buildsFiling coverage
4/5 membersproduct pipeline / R&D affecting expense
“The remaining increase was primarily due to a $6.0 million increase in activities supporting our ongoing clinical trials, a $5.0 million development milestone payment under the license agreement with Pfizer, and a $3.1 million increase in other costs primarily related to commercial launch activities.”
CELC 10-K
product pipeline / R&D
“The valuation allowance increased by $ 165.0 million and by $ 66.6 million for the years ended December 31, 2025 and 2024, respectively, primarily due to capitalized research and development expenditures and net operating losses carryforwards.”
ALMS 10-K
tariffs / trade costs
“However, the decision creates uncertainty related to various aspects of the tariffs previously collected under the IEEPA, and not all tariffs announced throughout 2025 were impacted by this U.S.”
CELC 10-K
Breadth and sponsorship may keep weakening, leaving the move isolated.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.